The first biosimilar for the treatment of breast and stomach cancers has been approved by the FDA, termed Ogivri.
In this commentary, Melanie Anderson discusses the use of paper-based dried sampling technologies and how they can provide opportunities to collect biological samples in the dried state, which involves significantly smaller sample volumes than traditional sample collection approaches.
MorphoSys (Munich, Germany) has announced that its licensee Janssen (Beerse, Belgium) has gained approval for Tremfya® in Europe. The monoclonal antibody is used for the treatment of plaque psoriasis.
The Good Clinical Laboratory Practice accreditation will enable the company to extend its proteomic services to the analysis of clinical trial samples.
The vaccine will be the first and only two-dose vaccine in the USA for the prevention of hepatitis B in adults, and the first new hepatitis B vaccine in the USA in over 25 years.
Lonza (Basel, Switzerland) announce the launch of four new services to expand their early phase biopharmaceutical drug development.
2. Given the complexity and cost of development and manufacturing, are biosimilars more affordable therapeutic options?
In this ‘Ask the Experts’ feature, the experts discuss the complexity and cost of development and whether biosimilars are more affordable therapeutic options.
12. How do you see the field evolving over the next 5-10 years? What are the main obstacles to be overcome?
In our final instalement, our experts look towards the future and comment on how they see the field evolving over the next 5-10 years.
Available to view on demand: In this webinar, Glenn Petrie discusses best practice in optimizing the Chemistry, Manufacturing and Control (CMC) process.
Charles River Laboratories (MA, USA) have acquired Brains On-Line (CA,USA), a CRO specializing in therapeutics for the treatment of CNS diseases.